6. Mai 2025 – Walder Wyss has advised Zurich-based Veraxa Biotech AG on its merger with Voyager Acquisition Corp, a Cayman Islands publicly traded Special Purpose Acquisition Company (SPAC) (Nasdaq: VACH). The signing was announced on 23 April 2025 and is set to be completed in Q4 2025. The whole deal will value Veraxa at up to USD 1.64 billion. Once finalized, Veraxa Biotech AG, together with its German subsidiary Veraxa Biotech GmbH, will become a Nasdaq-listed company, which remains focused on the development of a comprehensive pipeline of next-generation cancer therapies.

The Walder Wyss team was led by Marius Breier (Partner, Tax) and Thiemo Sturny (Partner, Corporate/M&A) and included Martina Madonna-Quadri (Senior Associate, Corporate/M&A), Maurus Winzap (Partner, Tax), Claude Schmid (Associate, Tax), Erik Lanz (Senior Associate, Corporate/M&A) and Gustaf Heintz (Senior Associate, Employment).